The effects of untreated and treated HIV infection on bone disease

Current Opinion in HIV and AIDS

Volumn 9, Issue 1, 2014, Pages 17-26

  Cotter, Aoife G ^a   Mallon, Patrick W G ^a,b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

B cells; bone; bone mineral density; fracture; HIV; immune dysfunction; T cells

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BONE DENSITY; BONE DISEASE; BONE METABOLISM; CD4 LYMPHOCYTE COUNT; FRACTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTI-RETROVIRAL AGENTS; BONE DENSITY; BONE DISEASES; HIV INFECTIONS; HUMANS; VIREMIA;

EID: 84892372044     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000028     Document Type: Review

References (68)

1. Schouten J, Wit F, Stolte IG, et al., on behalf of the AGEhIV Cohort Study Group. Comorbidity and ageing in HIV-1 infection: The AGEhIV Cohort Study. In: XIX International AIDS Conference, 22-27 July 2012. Washington, DC, USA; 2012
2. Graying plague: By 2015 over half of HIV in U.S. will be in those over 50. Late diagnoses contribute to problem. AIDS Alert 2010; 25: 25-28
3. Franco RA, Saag MS. When to start antiretroviral therapy: As soon as possible. BMC Med 2013; 11: 147
4. Lundgren JD, Babiker AG, Gordin FM, et al. When to start antiretroviral therapy: The need for an evidence base during early HIV infection. BMC Med 2013; 11: 148
5. Manolagas SC. Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115-137
6. Raisz LG. Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest 2005; 115: 3318-3325
7. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-Analytic review. AIDS 2006; 20: 2165-2174
8. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers. Clin Infect Dis 2010; 51: 937-946
9. Grijsen ML, Vrouenraets SM, Steingrover R, et al. High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS 2010; 24: 2233-2238
10. Grijsen ML, Vrouenraets SM, Wit FW, et al. Low bone mineral density, regardless of HIV status, in men who have sex with men. J Infect Dis 2013; 207: 386-391
11. Moore AL, Vashsiht A, Sabin CA, et al. Reduced bone mineral density in HIVpositive individuals. AIDS 2001; 15: 1731-1733
12. Knobel H, Guelar A, Vallecillo G, et al. Osteopenia in HIV-infected patients: Is it the disease or is it the treatment? AIDS 2001; 15: 807-808
13. Carr A, Miller J, Eisman JA, et al. Osteopenia in HIV-infected men: Association with asymptomatic lactic acidemia and lower weight pre-Antiretroviral therapy. AIDS 2001; 15: 703-709
14. Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV postmenopausal women. Osteoporos Int 2005; 16: 1345-1352
15. Sharma A, Flom PL, Weedon J, et al. Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS 2010; 24: 2337-2345
16. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36: 482-490
17. Fausto A, Bongiovanni M, Cicconi P, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone 2006; 38: 893-897
18. Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51: 554-561
19. Sharma A, Tian F, Yin MT, et al. Association of regional body composition with bone mineral density in HIV-infected and HIV-uninfected women: Women's interagency HIV study. J Acquir Immune Defic Syndr 2012; 61: 469-476
20. Bonjoch A, Figueras M, Estany C, et al. The prevalence of and progression to low bone mineral density in HIV-infected patients: A longitudinal cohort study. AIDS 2010; 24: 2827-2833
21. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: Prevalence and associated factors. AIDS 2008; 22: 395-402
22. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2006; 91: 2938-2945
23. Grant PM, Kitch D, McComsey GA, et al. Low baseline CD4 count is associated with greater bone mineral density loss after ART initiation. Clin Infect Dis 2013; 57: 1483-1488
24. Mary-Krause M, Viard JP, Ename-Mkoumazok B, et al. Prevalence of low bone mineral density in men and women infected with human immunodeficiency virus 1 and a proposal for screening strategy. J Clin Densitom 2012; 15: 422-433
25. Brown TT, Chen Y, Currier JS, et al. Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2013; 63: 323-330
26. Young B, Dao CN, Buchacz K, et al. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population. Clin Infect Dis 2011; 52: 1061-1068
27. Yong MK, Elliott JH, Woolley IJ, Hoy JF. Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr 2011; 57: 205-210
28. Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51: 554-561
29. Brown TT. HIV: An underrecognized secondary cause of osteoporosis? J Bone Miner Res 2013; 28: 1256-1258
30. McDermott AY, Shevitz A, Knox T, et al. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr 2001; 74: 679-686
31. Dube MP, Qian D, Edmondson-Melancon H, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002; 35: 475-481
32. Cauley JA, Danielson ME, Boudreau RM, et al. Inflammatory markers and incident fracture risk in older men and women: The Health Aging and Body Composition Study. J Bone Miner Res 2007; 22: 1088-1095
33. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203: 1791-1801
34. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51: 963-972
35. Martin A, Moore C, Mallon PW, et al. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS 2013; 27: 2403-2411
36. van Vonderen M, Mallon PWG, Murray B, et al.; for MEDICLAS Study Group. Changes in bone biomarkers in ARV nai?ve HIV men randomized to NVP/ LPV/r or AZT/3TC/LPV/r help explain limited loss of bone mineral density over the first 12 months after ART initiation. Paper # 833 18th Conference on Retroviruses and Opportunistic Infections, Boston, 2011
37. Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: Indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999; 84: 145-150
38. Bolland MJ, Wang TK, Grey A, et al. Stable bone density in HAART-Treated individuals with HIV: A meta-Analysis. J Clin Endocrinol Metab 2011; 96: 2721-2731
39. Cotter AG, Vrouenraets SM, Brady JJ, et al. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. J Clin Endocrinol Metab 2013; 98: 1659-1666
40. El-Sadr WM, Lundgren J, Neaton JD, et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296
41. Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009; 23: 1519-1529
42. Hoy J, Grund B, Roediger M, et al. Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy. J Bone Miner Res 2013; 28: 1264-1274
43. Bolland MJ, Grey A, Horne AM, et al. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART). Clin Endocrinol 2012; 76: 643-648
44. Yin MT, Lu D, Cremers S, et al. Short-Term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr 2010; 53: 202-208
45. Yin MT, Zhang CA, McMahon DJ, et al. Higher rates of bone loss in postmenopausal HIV-infected women: A longitudinal study. J Clin Endocrinol Metab 2012; 97: 554-562
46. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93: 3499-3504
47. Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 2011; 6: E17217
48. Hansen AB, Gerstoft J, Kronborg G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection: A Danish populationbased cohort study. AIDS 2012; 26: 285-293
49. Guerri-Fernandez R, Vestergaard P, Carbonell C, et al. HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: A population-based cohort study. J Bone Miner Res 2013; 28: 1259-1263
50. Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-Trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301: 513-521
51. US Department of Health and Human Services. Bone Health and Osteoporosis: A report of the Surgeon General. Rockville, MD, USA: US Department of Health and Human Services, Office of the Surgeon General, 2004
52. Li Y, Toraldo G, Li A, et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 2007; 109: 3839-3848
53. Choi Y, Kim JJ. B cells activated in the presence of Th1 cytokines inhibit osteoclastogenesis. Exp Mol Med 2003; 35: 385-392
54. Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep 2010; 7: 4-10
55. D'Amelio P, Grimaldi A, Di Bella S, et al. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: A key mechanism in osteoporosis. Bone 2008; 43: 92-100
56. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203: 2673-2682
57. Rifas L, Weitzmann MN. A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum 2009; 60: 3324-3335
58. Franco JM, Rubio A, Martinez-Moya M, et al. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood 2002; 99: 3702-3706
59. Kalayjian RC, Spritzler J, Pu M, et al. Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis 2005; 192: 1577-1587
60. Isgro A, Leti W, De Santis W, et al. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4 T cell counts despite viral suppression during HAART. Clin Infect Dis 2008; 46: 1902-1910
61. Ryan MR, Shepherd R, Leavey JK, et al. An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci USA 2005; 102: 16735-16740
62. Ofotokun I, Weitzmann N, Vunnava A, et al. HAART-induced immune reconstitution: A driving force behind bone resorption in HIV/AIDS. Paper # 78. 18th Conference on Retroviruses and Opportunistic Infections, Boston, 2011
63. Gazzola L, Bellistri GM, Tincati C, et al. Association between peripheral T-Lymphocyte activation and impaired bone mineral density in HIV-infected patients. J Transl Med 2013; 11: 51
64. Cotter EJ, Malizia AP, Chew N, et al. HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development. AIDS Res Hum Retroviruses 2007; 23: 1521-1530
65. Gibellini D, De Crignis E, Ponti C, et al. HIV-1 Tat protein enhances RANKL/ M-CSF-mediated osteoclast differentiation. Biochem Biophys Res Commun 2010; 401: 429-434
66. Fakruddin JM, Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 2005; 150: 67-78
67. Gibellini D, Borderi M, De Crignis E, et al. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol 2007; 79: 1446-1454
68. Vikulina T, Fan X, Yamaguchi M, et al. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad SciU SA 2010; 107: 13848-13853